LINC00324 facilitates cell proliferation through competing for miR‑214‑5p in immature ovarian teratocarcinoma

Chen,Meiling; Zhang,Min; Xie,Ling; Wu,Sanshan; Zhong,Yuanyuan

doi:10.3892/ijmm.2020.4800

LINC00324 facilitates cell proliferation through competing for miR‑214‑5p in immature ovarian teratocarcinoma

Authors:
- Meiling Chen
- Min Zhang
- Ling Xie
- Sanshan Wu
- Yuanyuan Zhong
View Affiliations

Affiliations: Gynecology Department, The First Hospital of Fuzhou Fujian, Fuzhou, Fujian 350009, P.R. China, Department of Orthopedic Trauma, Yidu Central Hospital, Weifang, Shandong 261000, P.R. China, Department of Gynecology, The First Hospital of Fuzhou Fujian, Fuzhou, Fujian 350009, P.R. China, Department of Obstetrics and Gynecology, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430013, P.R. China
Published online on: November 25, 2020 https://doi.org/10.3892/ijmm.2020.4800
Pages: 397-407

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immature ovarian teratocarcinoma (IOT) is a rare and malignant type of ovarian teratoma, and the molecular mechanisms underlying the pathogenesis and malignant phenotype of IOT remain uncharacterized. The present study examined a long non‑coding RNA (lncRNA), long‑chain intergenic non‑coding RNA324 (LINC00324), which may serve a crucial role in pathogenesis of IOT. According to the results, LINC00324 was upregulated in IOT tissues and cells, as determined by reverse transcription‑quantitative PCR, and its depletion impaired cell proliferation ability and improved cell apoptosis ability in IOT. Furthermore, LINC00324 acted as a miR‑214‑5p sponge to derepress cyclin dependent kinase 6 (CDK6), cyclin D1 (CCND1), murine double minute homolog 2 (MDM2), and mouse double minute 4 (MDM4) expression, thus increasing IOT cell proliferation and repressing apoptosis. Taken together, these results demonstrated that LINC00324 could serve as a competing endogenous RNA to facilitate IOT cell proliferation by regulation of miR‑214‑5p‑CDK6/CCND1/MDM2/MDM4 network, which possibly provide a novel therapeutic target for IOT.

View Figures

View References

1	Outwater EK, Siegelman ES and Hunt J: L: Ovarian teratomas: Tumor types and imaging characteristics. Radiographics. 21:475–490. 2001. View Article : Google Scholar : PubMed/NCBI
2	Jorge S, Jones NL, Chen L, Hou JY, Tergas AI, Burke WM, Ananth CV, Neugut AI, Herhshman DL and Wright JD: Characteristics, treatment and outcomes of women with immature ovarian teratoma, 1998-2012. Gynecol Oncol. 142:261–266. 2016. View Article : Google Scholar : PubMed/NCBI
3	Hung YC, Chang WC, Chen LM, Chang YY, Wu LY, Chung WM, Lin TY, Chen LC and Ma WL: Non-genomic estrogen/estrogen receptor α promotes cellular malignancy of immature ovarian teratoma in vitro. J Cell Physiol. 229:752–761. 2014. View Article : Google Scholar
4	Chan JK, Gardner AB, Chan JE, Guan A, Alshak M and Kapp DS: The influence of age and other prognostic factors associated with survival of ovarian immature teratoma-A study of 1307 patients. Gynecol Oncol. 142:446–451. 2016. View Article : Google Scholar : PubMed/NCBI
5	Eidem TM, Kugel JF and Goodrich JA: Noncoding RNAs: Regulators of the mammalian transcription machinery. J Mol Biol. 428:2652–2659. 2016. View Article : Google Scholar : PubMed/NCBI
6	Mattick JS and Makunin IV: Non-coding RNA. Hum Mol Genet. 15(Spec No 1): R17–R29. 2006. View Article : Google Scholar : PubMed/NCBI
7	Esteller M: Non-coding RNAs in human disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
8	Qi X, Zhang DH, Wu N, Xiao JH, Wang X and Ma W: ceRNA in cancer: Possible functions and clinical implications. J Med Genet. 52:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
9	Liu D, Li Y, Luo G, Xiao X, Tao D, Wu X, Wang M, Huang C, Wang L, Zeng F and Jiang G: LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. Cancer Lett. 388:281–291. 2017. View Article : Google Scholar
10	Huang J, Chen YX and Zhang B: IGF2-AS affects the prognosis and metastasis of gastric adenocarcinoma via acting as a ceRNA of miR-503 to regulate SHOX2. Gastric Cancer. 23:23–38. 2019. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
12	Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc. 1:2315–2319. 2006. View Article : Google Scholar
13	Chang RK, Li X, Mu N, Hrydziuszko O, Garcia-Majano B, Larsson C and Lui WO: MicroRNA expression profiles in non-epithelial ovarian tumors. Int J Oncol. 52:55–66. 2018.
14	Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e472015. View Article : Google Scholar : PubMed/NCBI
15	Zhu P, Wang Y, Wu J, Huang G, Liu B, Ye B, Du Y, Gao G, Tian Y, He L and Fan Z: LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells. Nat Commun. 7:136082016. View Article : Google Scholar : PubMed/NCBI
16	Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP: A ceRNA hypothesis: The rosetta stone of a hidden RNA language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
17	Li N, Zeng J, Sun F, Tong X, Meng G, Wu C, Ding X, Liu L, Han M, Lu C and Dai F: p27 inhibits CDK6/CCND1 complex formation resulting in cell cycle arrest and inhibition of cell proliferation. Cell Cycle. 17:2335–2348. 2018. View Article : Google Scholar : PubMed/NCBI
18	Li Q and Lozano G: Molecular pathways: Targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res. 19:34–41. 2013. View Article : Google Scholar :
19	Siddik ZH: Chapter 12-Apoptosis in cancer: Mechanisms, deregulation, and therapeutic targeting. Cancer Drug Design and Discovery. Neidle S: 2nd edition. Academic Press; San Diego, CA: pp. 357–390. 2014, View Article : Google Scholar
20	Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011. View Article : Google Scholar : PubMed/NCBI
21	Zhao Y, Ponnusamy M, Zhang L, Zhang Y, Liu C, Yu W, Wang K and Li P: The role of miR-214 in cardiovascular diseases. Eur J Pharmacol. 816:138–145. 2017. View Article : Google Scholar : PubMed/NCBI
22	Zheng C, Guo K, Chen B, Wen Y and Xu Y: MiR-214-5p inhibits human prostate cancer proliferation and migration through regulating CRMP5. Cancer Biomark. 26:193–202. 2019. View Article : Google Scholar : PubMed/NCBI
23	Pang J, Li Z, Wang G, Li N, Gao Y and Wang S: MiR-214-5p targets KLF5 and suppresses proliferation of human hepatocellular carcinoma cells. J Cell Biochem. Sep 11–2018.Epub ahead of print.
24	Cao TH, Ling X, Chen C, Tang W, Hu DM and Yin GJ: Role of miR-214-5p in the migration and invasion of pancreatic cancer cells. Eur Rev Med Pharmacol Sci. 22:7214–7221. 2018.PubMed/NCBI
25	Wu S, Gu Z, Wu Y, Wu W, Mao B and Zhao S: LINC00324 accelerates the proliferation and migration of osteosarcoma through regulating WDR66. J Cell Physiol. 235:339–348. 2020. View Article : Google Scholar
26	Pan ZH, Guo XQ, Shan J and Luo SX: LINC00324 exerts tumor-promoting functions in lung adenocarcinoma via targeting miR-615-5p/AKT1 axis. Eur Rev Med Pharmacol Sci. 22:8333–8342. 2018.PubMed/NCBI
27	Zou Z, Ma T, He X, Zhou J, Ma H, Xie M, Liu Y, Lu D, Di S and Zhang Z: Long intergenic non-coding RNA 00324 promotes gastric cancer cell proliferation via binding with HuR and stabilizing FAM83B expression. Cell Death Dis. 9:7172018. View Article : Google Scholar : PubMed/NCBI
28	VanArsdale T, Boshoff C, Arndt KT and Abraham RT: Molecular pathways: Targeting the cyclin D-CDK4/6 axis for cancer treatment. Clin Cancer Res. 21:2905–2910. 2015. View Article : Google Scholar : PubMed/NCBI
29	Jirawatnotai S, Hu Y, Livingston DM and Sicinski P: Proteomic identification of a direct role for cyclin d1 in DNA damage repair. Cancer Res. 72:4289–4293. 2012. View Article : Google Scholar : PubMed/NCBI
30	Shadfan M, Lopez-Pajares V and Yuan ZM: MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res. 1:88–89. 2012.PubMed/NCBI